Bessemer Group’s Dianthus Therapeutics DNTH Stock Holding History

Bessemer Group’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.47M	Sell	15,124 -1,010	-6%	-$88.2K	﹤0.01%	923
2026 Q1	$1.35M	Sell	16,134 -21	-0.1%	-$1.22K	﹤0.01%	894
2025 Q4	$666K	Buy	16,155 +21	+0.1%	+$814	﹤0.01%	1062
2025 Q3	$635K	Buy	16,134 +1,170	+8%	+$29.9K	﹤0.01%	776
2025 Q2	$279K	Buy	14,964 +135	+0.9%	+$2.53K	﹤0.01%	1015
2025 Q1	$269K	Hold	14,829	–	–	﹤0.01%	1025
2024 Q4	$323K	Hold	14,829	–	–	﹤0.01%	988
2024 Q3	$406K	Hold	14,829	–	–	﹤0.01%	951
2024 Q2	$384K	Hold	14,829	–	–	﹤0.01%	871
2024 Q1	$445K	Hold	14,829	–	–	﹤0.01%	839
2023 Q4	$154K	Hold	14,829	–	–	﹤0.01%	1098
2023 Q3	$203K	Sell	14,829 -2	-0%	-$25	﹤0.01%	1028
2023 Q2	$180K	Hold	14,831	–	–	﹤0.01%	1077
2023 Q1	$189K	Hold	14,831	–	–	﹤0.01%	910
2022 Q4	$94K	Buy	14,831 +1	+0%	+$18	﹤0.01%	1051
2022 Q3	$335K	Hold	14,830	–	–	﹤0.01%	810
2022 Q2	$285K	Hold	14,830	–	–	﹤0.01%	816
2022 Q1	$688K	Hold	14,830	–	–	﹤0.01%	558
2021 Q4	$1.05M	Hold	14,830	–	–	﹤0.01%	450
2021 Q3	$1.73M	Hold	14,830	–	–	﹤0.01%	334
2021 Q2	$2.32M	Hold	14,830	–	–	0.01%	304
2021 Q1	$2.81M	Hold	14,830	–	–	0.01%	290
2020 Q4	$1.86M	Hold	14,830	–	–	﹤0.01%	311
2020 Q3	$1.61M	Hold	14,830	–	–	﹤0.01%	347
2020 Q2	$1.78M	Hold	14,830	–	–	0.01%	521
2020 Q1	$1.49M	Hold	14,830	–	–	0.01%	504
2019 Q4	$3.6M	Hold	14,830	–	–	0.01%	409
2019 Q3	$2.43M	Hold	14,830	–	–	0.01%	465
2019 Q2	$3.5M	Hold	14,830	–	–	0.01%	391
2019 Q1	$3.91M	Hold	14,830	–	–	0.02%	317
2018 Q4	$1.35M	Buy	+14,830	New	+$2.02M	0.01%	500

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Bessemer Group's DNTH Position: Q2 2026 in Review

Bessemer Group reduced its Dianthus Therapeutics (DNTH) stake by 6.3% in Q2 2026, selling an estimated $88.2K and leaving 15,124 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #923.

Bessemer Group first reported a position in DNTH in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.91M in Q1 2019. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Bessemer Group held 15,124 shares of Dianthus Therapeutics worth $1.47M as of Q2 2026.
Bessemer Group sold 1,010 Dianthus Therapeutics shares in Q2 2026, an estimated $88.2K.
Dianthus Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #923 holding.
Bessemer Group first reported a position in Dianthus Therapeutics in Q4 2018 and has held it in 31 quarters since.
Bessemer Group's Dianthus Therapeutics position peaked at $3.91M in Q1 2019.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.